We are developing multi-therapeutics that focus on the central nervous system. Our research programs aim to explore the potential of our scientific discovery in addressing a broad range of inflammatory-based brain health concerns.
Our clinical research programs focus on evaluating the scientific efficacy of our neuroprotective compounds and plays a vital role in helping advance the field of brain health.
We anticipate trial initiation for our early stage Alzheimer’s disease trials in Q1 2019.
To learn more about our early stage Alzheimer's disease trials contact: email@example.com.
We are currently enrolling individuals diagnosed with post-traumatic stress disorder (PTSD) to test the therapeutic potential of NeuroSHIELD™ in alleviating symptoms of PTSD.
To learn more about our PTSD study contact: firstname.lastname@example.org.